Olympia's Circulate Aims to Reshape IV Nutritional Therapy

ORLANDO, Fla. – February 18, 2026 – Olympia Pharmaceuticals, a prominent national compounding pharmacy, today announced the launch of Circulate, a new single-dose intravenous (IV) nutritional therapy designed to support vascular health. The ready-to-use premix marks a significant expansion of the company's immediate-use IV product line, aiming to merge targeted nutritional science with major improvements in clinical efficiency for healthcare providers.

The new formulation combines Arginine, Niacinamide, Pyridoxine, and Taurine—a blend of amino acids and vitamins specifically chosen for their roles in supporting microcirculation, endothelial resilience, and overall systemic health. By offering this specialized formula in a premixed format, Olympia is addressing a growing demand in the wellness market for solutions that are both scientifically robust and operationally simple.

Unpacking the Science of Vascular Support

While the concept of IV nutritional therapy has gained mainstream popularity for general wellness, Circulate represents a more targeted approach, focusing squarely on the complex mechanisms of the cardiovascular system. The efficacy of the formula is rooted in the established physiological roles of its individual components.

At the core of the blend is L-Arginine, an amino acid that functions as a precursor to nitric oxide (NO). In the body, nitric oxide is a critical vasodilator, meaning it helps relax and widen blood vessels, which improves blood flow and helps regulate blood pressure. Decades of research have shown that intravenous L-Arginine can enhance endothelial function, the health of the inner lining of blood vessels, which is crucial for preventing cardiovascular disease.

Circulate also includes Niacinamide (Vitamin B3), a key component in the synthesis of NAD+, a coenzyme vital for cellular energy production and antioxidant defense. While not possessing the same lipid-altering effects as its cousin, nicotinic acid, niacinamide's anti-inflammatory and antioxidant properties help protect the vascular endothelium from oxidative stress, a primary driver of arterial damage.

Further bolstering the formula is Pyridoxine (Vitamin B6). This vitamin is essential for metabolizing homocysteine, an amino acid that, at elevated levels, is a well-known risk factor for cardiovascular disease. High homocysteine can damage blood vessel walls and increase the risk of atherosclerosis. By facilitating the conversion of homocysteine into other substances, Pyridoxine helps protect the integrity of the vascular system. The final key ingredient, Taurine, is a sulfur-containing amino acid abundant in the heart and blood vessels. It provides multiple cardioprotective benefits, including maintaining the electrolyte balance necessary for a steady heart rhythm, regulating blood pressure, and acting as a potent antioxidant to shield vascular tissue from damage.

Administering this combination intravenously allows for nearly 100% bioavailability, bypassing the digestive system to deliver the nutrients directly into the bloodstream for immediate use by the body’s cells.

The Ready-to-Use Revolution in Clinical Practice

Beyond its scientific formulation, Circulate's primary innovation lies in its delivery format. The single-dose, premixed solution is designed to fundamentally streamline workflows in busy clinics and medical practices, a pain point Olympia aims to solve.

“The introduction of Circulate reflects our commitment to advancing IV nutritional therapy,” said Mark Mikhael, CEO of Olympia Pharmaceuticals, in the company's announcement. “By expanding our single-dose premix injection line, we are empowering providers to offer high-impact wellness solutions while streamlining the delivery process for a smoother patient experience.”

Traditionally, preparing a multi-ingredient IV drip requires a trained clinician to draw individual nutrients from separate vials and inject them into a sterile saline bag. This manual process is not only time-consuming but also introduces multiple opportunities for human error, including incorrect dosages or microbial contamination from repeated bag punctures. Circulate eliminates these steps. As a ready-to-use solution, it drastically reduces preparation time, minimizes the risk of compounding errors, and enhances patient safety through a standardized, quality-controlled product.

“Our focus at Olympia has always been to create practical solutions that meet the evolving demands of modern practices,” noted Stan Loomis, co-founder of Olympia Pharmaceuticals. “With the introduction of Circulate, we are providing a vital resource that balances nutritional potency with operational simplicity, allowing providers to focus more on patient care and less on complex logistics.”

For high-volume wellness centers and medical spas, this efficiency can translate to higher patient throughput and allows clinical staff to dedicate more time to direct patient care rather than back-room preparation.

Quality and Scale Under the 503B Framework

Crucial to Olympia's ability to offer a product like Circulate is its dual status as both a 503A and an FDA-registered 503B compounding facility. This regulatory distinction is key to understanding the product's quality and market availability. While traditional 503A pharmacies compound medications for individual patients based on specific prescriptions, 503B outsourcing facilities operate under a different, more stringent set of rules.

Registered with and regulated by the FDA, 503B facilities must adhere to current Good Manufacturing Practices (cGMP), the same quality standards required of major pharmaceutical manufacturers. This framework allows them to produce larger, uniform batches of sterile medications for “office use” without patient-specific prescriptions. For healthcare providers, sourcing products from a 503B facility provides a high level of assurance regarding the drug's sterility, potency, and stability.

By manufacturing Circulate under these cGMP standards, Olympia can guarantee a consistent and reliable product that clinics can stock and administer with confidence. This regulatory oversight mitigates risks for providers and differentiates products like Circulate from those prepared in less-regulated settings, offering a clear advantage in safety and quality.

Tapping into an Expanding Wellness Market

The launch of Circulate is strategically timed, capitalizing on a booming market for IV nutritional therapies. The global market, valued at nearly $13 billion in recent years, is projected to grow at a compound annual rate of over 8% through the next decade. This growth is fueled by a cultural shift towards preventative health, a rising interest in personalized medicine, and an aging population seeking solutions for longevity and vitality.

Consumers are increasingly proactive, seeking out therapies that go beyond treating sickness and instead focus on optimizing health. IV therapy, once confined to hospitals, is now a staple in wellness clinics, medical spas, and anti-aging centers. Olympia's strategy appears to be a direct response to this evolution. Circulate joins the company’s existing Myers’ Cocktail Premix, building a portfolio of ready-to-use solutions that cater to the most common wellness demands.

By offering a targeted, science-backed product that also solves a major logistical challenge for providers, Olympia is positioning itself not just as a supplier but as a key partner to the clinics on the front lines of this wellness movement. As the demand for safe, effective, and convenient nutritional therapies continues to grow, solutions that combine scientific credibility with operational simplicity are poised to define the future of the market.